p21Waf1/Cip1 as a therapeutic target in breast and other cancers

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

The cyclin kinase inhibitor p21, originally described as a universal inhibitor of cyclin-dependent kinases, has since been shown to have additional functions other than CDK inhibition. It is likely that a key role of p21 is to keep cells alive after DNA damage and subsequent p53 induction, in order for the cell to effect repairs. Thus, the increase in p21 seen in some cancers may impart these cells with a survival advantage. Here we discuss how this antiapoptotic aspect of p21 makes it an attractive target for cancer therapy; attenuation of p21 in malignant cells may subvert the normal repair process induced by DNA-damaging chemotherapeutic agents and thus make such drugs more effective.

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalCancer Cell
Volume4
Issue number6
DOIs
StatePublished - Dec 2003

Fingerprint

Breast Neoplasms
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases
Therapeutics
DNA Damage
Neoplasms
DNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

p21Waf1/Cip1 as a therapeutic target in breast and other cancers. / Weiss, Robert H.

In: Cancer Cell, Vol. 4, No. 6, 12.2003, p. 425-429.

Research output: Contribution to journalArticle

@article{081021bd8ccf4079a1b686732e0d7650,
title = "p21Waf1/Cip1 as a therapeutic target in breast and other cancers",
abstract = "The cyclin kinase inhibitor p21, originally described as a universal inhibitor of cyclin-dependent kinases, has since been shown to have additional functions other than CDK inhibition. It is likely that a key role of p21 is to keep cells alive after DNA damage and subsequent p53 induction, in order for the cell to effect repairs. Thus, the increase in p21 seen in some cancers may impart these cells with a survival advantage. Here we discuss how this antiapoptotic aspect of p21 makes it an attractive target for cancer therapy; attenuation of p21 in malignant cells may subvert the normal repair process induced by DNA-damaging chemotherapeutic agents and thus make such drugs more effective.",
author = "Weiss, {Robert H}",
year = "2003",
month = "12",
doi = "10.1016/S1535-6108(03)00308-8",
language = "English (US)",
volume = "4",
pages = "425--429",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - p21Waf1/Cip1 as a therapeutic target in breast and other cancers

AU - Weiss, Robert H

PY - 2003/12

Y1 - 2003/12

N2 - The cyclin kinase inhibitor p21, originally described as a universal inhibitor of cyclin-dependent kinases, has since been shown to have additional functions other than CDK inhibition. It is likely that a key role of p21 is to keep cells alive after DNA damage and subsequent p53 induction, in order for the cell to effect repairs. Thus, the increase in p21 seen in some cancers may impart these cells with a survival advantage. Here we discuss how this antiapoptotic aspect of p21 makes it an attractive target for cancer therapy; attenuation of p21 in malignant cells may subvert the normal repair process induced by DNA-damaging chemotherapeutic agents and thus make such drugs more effective.

AB - The cyclin kinase inhibitor p21, originally described as a universal inhibitor of cyclin-dependent kinases, has since been shown to have additional functions other than CDK inhibition. It is likely that a key role of p21 is to keep cells alive after DNA damage and subsequent p53 induction, in order for the cell to effect repairs. Thus, the increase in p21 seen in some cancers may impart these cells with a survival advantage. Here we discuss how this antiapoptotic aspect of p21 makes it an attractive target for cancer therapy; attenuation of p21 in malignant cells may subvert the normal repair process induced by DNA-damaging chemotherapeutic agents and thus make such drugs more effective.

UR - http://www.scopus.com/inward/record.url?scp=0347628818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347628818&partnerID=8YFLogxK

U2 - 10.1016/S1535-6108(03)00308-8

DO - 10.1016/S1535-6108(03)00308-8

M3 - Article

C2 - 14706334

AN - SCOPUS:0347628818

VL - 4

SP - 425

EP - 429

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -